{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T07:13:43Z","timestamp":1716275623158},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,12,9]],"date-time":"2013-12-09T00:00:00Z","timestamp":1386547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,12,9]],"date-time":"2013-12-09T00:00:00Z","timestamp":1386547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1038\/bmt.2013.189","type":"journal-article","created":{"date-parts":[[2013,12,9]],"date-time":"2013-12-09T11:35:38Z","timestamp":1386588938000},"page":"422-425","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Value of novel agents and intensive therapy for patients with multiple myeloma"],"prefix":"10.1038","volume":"49","author":[{"given":"R","family":"Alexanian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Delasalle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Qazilbash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Handy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,12,9]]},"reference":[{"key":"BFbmt2013189_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91\u201397.","journal-title":"N Engl J Med"},{"key":"BFbmt2013189_CR2","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"J Child","year":"2003","unstructured":"Child J, Morgan G, Davies F, Owen R, Bell S, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Eng J Med 2003; 348: 1875\u20131883.","journal-title":"N Eng J Med"},{"key":"BFbmt2013189_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","volume":"21","author":"D Weber","year":"2003","unstructured":"Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R . Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16\u201319.","journal-title":"J Clin Oncol"},{"key":"BFbmt2013189_CR4","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1200\/JCO.2002.02.116","volume":"20","author":"SV Rajkumar","year":"2002","unstructured":"Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 4319\u20134323.","journal-title":"J Clin Oncol"},{"key":"BFbmt2013189_CR5","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1200\/JCO.2008.18.3087","volume":"27","author":"PG Richardson","year":"2009","unstructured":"Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, Hassoun H et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 2009; 27: 3518\u20133525.","journal-title":"J Clin Oncol"},{"key":"BFbmt2013189_CR6","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/j.1365-2141.2005.05540.x","volume":"129","author":"S Jagannath","year":"2005","unstructured":"Jagannath S, Durie BG, Wolf J, Camacho E, Irwin D, Lutzky J et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129: 776\u2013783.","journal-title":"Br J Haematol"},{"key":"BFbmt2013189_CR7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1080\/10245330701214236","volume":"12","author":"M Wang","year":"2007","unstructured":"Wang M, Giralt S, Delasalle K, Handy B, Alexanian R . Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology 2007; 12: 235\u2013239.","journal-title":"Hematology"},{"key":"BFbmt2013189_CR8","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1179\/102453310X12583347010133","volume":"15","author":"M Wang","year":"2010","unstructured":"Wang M, Delasalle K, Giralt S, Alexanian R . Rapid control of previously untreated multiple myeloma with bortezomib\u2014lenalidomide\u2014dexamethasone. Hematology 2010; 15: 70\u201373.","journal-title":"Hematology"},{"key":"BFbmt2013189_CR9","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/bmt.2009.176","volume":"45","author":"M Wang","year":"2009","unstructured":"Wang M, Delasalle K, Feng L, Thomas S, Giralt S, Qazilbash M et al. CR represents an early index of potential long survival in multiple myeloma. Bone Marrow Transplant 2009; 45: 498\u2013504.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2013189_CR10","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blad\u00e9 J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412\u20133420.","journal-title":"J Clin Oncol"},{"key":"BFbmt2013189_CR11","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1038\/sj.bmt.1703035","volume":"27","author":"R Alexanian","year":"2001","unstructured":"Alexanian R, Weber D, Giralt S, Dimopoulos M, Delasalle K, Smith T et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001; 27: 1037\u20131043.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2013189_CR12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/sj.bmt.1704562","volume":"34","author":"R Alexanian","year":"2004","unstructured":"Alexanian R, Weber D, Delasalle K, Handy B, Champlin R, Giralt S . Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma. Bone Marrow Transplant 2004; 34: 229\u2013234.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2013189_CR13","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"B Durie","year":"2006","unstructured":"Durie B, Harousseau JL, Miguel J, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467\u20131473.","journal-title":"Leukemia"},{"key":"BFbmt2013189_CR14","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","volume":"102","author":"J Blade","year":"1998","unstructured":"Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115\u20131123.","journal-title":"Br J Haematol"},{"key":"BFbmt2013189_CR15","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"E Kaplan","year":"1958","unstructured":"Kaplan E, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457\u2013481.","journal-title":"J Am Stat Assoc"},{"key":"BFbmt2013189_CR16","first-page":"163","volume":"50","author":"N Mantel","year":"1966","unstructured":"Mantel N . Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemotherapy Rep 1966; 50: 163\u2013170.","journal-title":"Cancer Chemotherapy Rep"},{"key":"BFbmt2013189_CR17","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1200\/JCO.1983.1.11.710","volume":"1","author":"J Anderson","year":"1983","unstructured":"Anderson J, Cain K, Gelber R . Analysis of survival by tumor response. J Clin Oncol 1983; 1: 710\u2013719.","journal-title":"J Clin Oncol"},{"key":"BFbmt2013189_CR18","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"D Cox","year":"1972","unstructured":"Cox D . Regression models and life tables. J Royal Stat Soc 1972; 34: 187\u2013220.","journal-title":"J Royal Stat Soc"},{"key":"BFbmt2013189_CR19","doi-asserted-by":"publisher","first-page":"5775","DOI":"10.1200\/JCO.2008.17.9721","volume":"26","author":"J Lahuerta","year":"2008","unstructured":"Lahuerta J, Mateos M, Martinez-Lopez J, Rosinol L, Sureda A, de la Rubia J et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 2008; 26: 5775\u20135782.","journal-title":"J Clin Oncol"},{"key":"BFbmt2013189_CR20","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1182\/blood-2009-07-235531","volume":"115","author":"M Gertz","year":"2010","unstructured":"Gertz M, Kumar S, Lacy M, Dispenzeri A, Dingli D, Hayman S et al. Stem cell transplantation in multiple myeloma; impact of response failure with thalidomide or lenalidomide induction. Blood 2010; 115: 2348\u20132353.","journal-title":"Blood"},{"key":"BFbmt2013189_CR21","first-page":"87","volume":"124","author":"I Snapper","year":"1964","unstructured":"Snapper I, Kahn A . Multiple Myeloma. Semin Hematol 1964; 124: 87\u2013143.","journal-title":"Semin Hematol"},{"key":"BFbmt2013189_CR22","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/cncr.23546","volume":"113","author":"B Barlogie","year":"2008","unstructured":"Barlogie B, Anaissie E, Haessler J, van Rhee F, Pineda-Roman M, Hollmig K et al. Complete remission sustained for 3 years from treatment initiation is a powerful surrogate marker for extended survival in multiple myeloma. Cancer 2008; 113: 355\u2013359.","journal-title":"Cancer"},{"key":"BFbmt2013189_CR23","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/bmt.2008.166","volume":"42","author":"S Kumar","year":"2008","unstructured":"Kumar S, Dingli S, Dispenzeri A, Lacy M, Hayman S, Buadi F et al. Impact of additional cytoreduction following autologous SCT in multiple myeloma. Bone Marrow Transplant 2008; 42: 259\u2013264.","journal-title":"Bone Marrow Transplant"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2013189.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2013189","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2013189.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T06:41:31Z","timestamp":1716273691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2013189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,9]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["BFbmt2013189"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2013.189","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,9]]},"assertion":[{"value":"16 May 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}